Peeved by price gouging and shortages, hospitals will now make their own drugs | Ars Technica

In an interview with The New York Times, Intermountain Healthcare’s CEO, Dr. Marc Harrison, did not mince words. “This is a shot across the bow of the bad guys,” he said. “We are not going to lay down. We are going to go ahead and try and fix it.”

The news—and furor—follows years of headlines, scandals, and congressional hearings over certain drug companies dramatically raising the prices of generic drugs and creating frustrating shortages. The most notable example is that of Martin Shkreli’s company Turing Pharmaceuticals, which dramatically raised the price of the old, cheap generic drug Daraprim by more than 5,000 percent—from $13.50 to $750 a pill. Daraprim is used to treat a parasitic infection and often given to babies and HIV/AIDS patients.

The group is not disclosing what specific medicines it will make out of fear that generic competitors could block them from the market by lowering prices temporarily. “We’re going to have to hold that very close to our vest,” Dr. Harrison told The Times.

Read complete article here:

Peeved by price gouging and shortages, hospitals will now make their own drugs | Ars Technica.

Post a Comment

WP-SpamFree by Pole Position Marketing